Q4 2020 13F Holders as of 12/31/2020
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
70.9M
-
Number of holders
-
73
-
Total 13F shares, excl. options
-
22.2M
-
Shares change
-
+21.5M
-
Total reported value, excl. options
-
$728M
-
Value change
-
+$703M
-
Number of buys
-
68
-
Price
-
$33.13
Significant Holders of C4 Therapeutics, Inc. - Common Stock (CCCC) as of Q4 2020
73 filings reported holding CCCC - C4 Therapeutics, Inc. - Common Stock as of Q4 2020.
C4 Therapeutics, Inc. - Common Stock (CCCC) has 73 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 22.2M shares
of 70.9M outstanding shares and own 31.38% of the company stock.
Largest 10 shareholders include PERCEPTIVE ADVISORS LLC (3.16M shares), Cormorant Asset Management, LP (2.49M shares), RTW INVESTMENTS, LP (2.15M shares), Bain Capital Life Sciences Investors, LLC (1.64M shares), PRICE T ROWE ASSOCIATES INC /MD/ (1.53M shares), RA CAPITAL MANAGEMENT, L.P. (1.38M shares), JANUS HENDERSON GROUP PLC (1.3M shares), BlackRock Inc. (1.14M shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (890K shares), and FMR LLC (671K shares).
This table shows the top 73 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.